» Articles » PMID: 15717277

Poliovirus-specific Memory Immunity in Seronegative Elderly People Does Not Protect Against Virus Excretion

Overview
Journal J Infect Dis
Date 2005 Feb 18
PMID 15717277
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Dutch people born between 1925 and 1945 were ineligible for vaccination with the inactivated poliovirus vaccine (IPV) introduced in 1957 and may have escaped natural infection because of reduced poliovirus circulation. We examined whether people with low or undetectable antibody levels are susceptible to infection and whether memory immunity provides protection against virus excretion.

Methods: A total of 429 elderly participants were challenged with monovalent oral poliovirus vaccine (type 1 or 3) and followed for 8 weeks. Immune responses and virus excretion were compared for 4 groups, defined on the basis of seronegativity for poliovirus type 1 or 3, natural immunity, and IPV-induced immunity.

Results: On the basis of the rapidity of the antibody response and the absence of immunoglobulin M, we saw clear evidence of memory immune responses in 33% of the participants without detectable antibodies against poliovirus type 1 and in 5% of the participants without detectable antibodies against poliovirus type 3. Fecal virus-excretion patterns were not significantly different for seronegative participants, regardless of whether they showed evidence of memory immunity.

Conclusions: Rapid antibody responses after challenge with oral polio vaccine provide evidence for poliovirus-specific memory immunity in seronegative elderly people. However, in contrast to preexisting immunity, memory immunity does not protect against virus excretion. These results have important implications for the poliomyelitis-eradication initiative, in particular for future immunization policies after eradication has been achieved.

Citing Articles

Immunodeficiency-Related Vaccine-Derived Poliovirus (iVDPV) Infections: A Review of Epidemiology and Progress in Detection and Management.

Estivariz C, Krow-Lucal E, Mach O Pathogens. 2025; 13(12).

PMID: 39770387 PMC: 11677883. DOI: 10.3390/pathogens13121128.


A literature review and evidence-based evaluation of the Dutch national immunisation schedule yield possibilities for improvements.

Pluijmaekers A, Steens A, Houweling H, Rots N, Benschop K, van Binnendijk R Vaccine X. 2024; 20:100556.

PMID: 39444596 PMC: 11497366. DOI: 10.1016/j.jvacx.2024.100556.


Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological survey.

Trueba G, Jeyaseelan V, Lopez L, Mainou B, Zhang Y, Whittembury A Lancet Reg Health Am. 2022; 11:None.

PMID: 35865654 PMC: 9283112. DOI: 10.1016/j.lana.2022.100235.


Poliovirus immunity among adults in the Democratic Republic of the Congo: a cross-sectional serosurvey.

Alfonso V, Voorman A, Hoff N, Weldon W, Gerber S, Gadoth A BMC Infect Dis. 2022; 22(1):30.

PMID: 34986786 PMC: 8728990. DOI: 10.1186/s12879-021-06951-6.


Mucosal immunity to poliovirus.

Connor R, Brickley E, Wieland-Alter W, Ackerman M, Weiner J, Modlin J Mucosal Immunol. 2021; 15(1):1-9.

PMID: 34239028 PMC: 8732262. DOI: 10.1038/s41385-021-00428-0.